Risk factor
High price volatility
Profitability factor
Favourable analyst view
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
BeiGene Ltd. is a global biotechnology enterprise, grounded in scientific research, committed to developing groundbreaking and economical pharmaceutical products. Its core mission is to enhance therapeutic outcomes and broaden patient access to critical medicines across the world. The company was co-founded by Xiao Dong Wang and John V. Oyler on October 28, 2010, and its corporate headquarters are situated in George Town, KY.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of 6160.HK is 257 and suggests 39.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in